JPRN-C000000143未知1 期
A combination phase I study of topotecan with cisplatin for elderly small cell lung cancer - A combination phase I study of topotecan with cisplatin for elderly small cell lung cancer
Department of Medical Oncology, Kinki University School of Medicine0 个研究点目标入组 28 人开始时间: 2005年9月8日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 70years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Severe infection and complication (hemorrhage and heart disease etc.) 2)Intestinal pneumonia or lung fibrosis 3)Symptomatic brain metastasis 4)History of active other malignancy 5)History of severe drug allergic reaction 6)Pregnant women or women willing child-bearing 7)Men willing to have children 8)Uncontrolled diabetes 9)Uncontrolled pleural, cardiac, or abdominal effusion 10)Inadequate condition diagnosed by primary physician
研究者
相似试验
已完成
1 期
A combination phase I/II study of topotecan with carboplatin for relapsed small cell lung cancerrelapsed small cell lung cancerJPRN-C000000128West Japan Oncology Group38
尚未招募
1 期
Reducing hypoxia in patients with COVID-19 using Topotecan with standard of careCTRI/2021/08/035537ational University Cancer Institute of Singapore NCIS National University Hospital Singapore
已完成
1 期
Topotecan in Combination With Pemetrexed in Patients With Advanced MalignanciesEndometrial CancerLung CancerOvarian CancerCervical CancerNCT00315861SCRI Development Innovations, LLC15
尚未招募
1 期
Reducing systemic inflammation in cancer patients with COVID-19 using Topotecan with Dexamethasone and RemdesivirCTRI/2021/03/031969ational University Cancer Institute of Singapore NCIS National University Hospital Singapore
已完成
1 期
Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid TumorsCancerNCT00193570SCRI Development Innovations, LLC20